Despite encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from pharmacy benefit managers. The insurers are https://sabrinarpfi953575.tusblogos.com/42709819/the-vyndamax-faces-is-meeting-managed-care-organization-hurdles-the-review-at-coverage-fights